GOG 0241 Ovarian/Fallopian Tube/Primary Peritoneal Cancer: MUCINOUS EPITHELIAL OVARIAN OR FALLOPIAN TUBE CANCER
GOG-0241 A GCIG INTERGROUP MULTICENTER PHASE III TRIAL OF OPEN LABEL CARBOPLATIN & PACLITAXEL +/- NCI-SUPPLIED AGENT: BEVACIZUMAB COMPARED w OXALIPLATIN & CAPECITABINE +/- BEVACIZUMAB AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH MUCINOUS EPITHELIAL OVARIAN OR FALLOPIAN TUBE CANCER (MEOC)
Patients may have measurable disease as defined by RECIST 1.1 or no measurable
3.12 All patients must have had appropriate surgery including appendectomy (unless
patient has history of prior appendectomy) for ovarian or fallopian tube
carcinoma with appropriate tissue available for histologic evaluation to confirm
diagnosis and stage.
3.13 Patients must have stage II-IV disease (no brain metastasis) or recurrent Stage I